Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might ...
Dr. Yeu serves as a partner and practicing ophthalmologist at Virginia Eye Consultants, where she will continue her clinical practice. Dr. Yeu has authored hundreds of publications and is a renowned ...
Harbor Capital Advisors Inc. raised its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 57.5% in the third quarter, according to the company in its most recent filing ...
the first and only FDA approved treatment for Demodex blepharitis (DB). Demodex blepharitis occurs when Demodex mites – the most common ectoparasites found on humans – overpopulate on the eyelids.
This spot treatment is a favorite of both Gohara and Jaber, and can reduce the size and redness of acne in just two hours, according to the brand. It contains 10% benzoyl peroxide, which inhibits ...
There are four main approaches to treatment—psychotherapy, antidepressant medications, neuromodulation, and lifestyle measures—and all address different facets of the disorder.